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Purpose: To evaluate the survival of patients with human epidermal growth factor receptor 2 (HER2) positive and
negative metastatic breast cancer irradiated for brain metastases before and after the availability of trastuzumab (T).
Materials and methods: Women diagnosed with brain metastasis from breast cancer in two eras between 2000
and 2007 (T-era, n = 441) and 1986 to 1992 (PreT-era, n = 307), treated with whole brain radiotherapy (RT) were
identified. In the T-era, HER2 testing was part of routine clinical practice, and in the preT-era 128/307 (42%) cases
had HER2 testing performed retrospectively on tissue microarrays. Overall survival (OS) was estimated using the
Kaplan-Meier method and comparisons between eras used log-rank tests.
Results: In the preT- and T-era cohorts, the rate of HER2 positivity was 40% (176/441) and 26% (33/128) (p < 0.001).
The median time from diagnosis to brain RT was longer in the preT-era (3.3 years versus 2.3 years, p < 0.001).
Survival after brain RT was improved in the T-era compared to the preT-era (1-year OS 26% versus 12%, p < 0.001).
The 1-year OS rate for HER2 negative patients was 20% in both eras (p = 0.97). Among HER2 positive patients, the
1-year OS in the preT-era was 5% compared to 40% in the T-era (p < 0.001).
Conclusions: Distinct from patients with HER2 negative disease in whom no difference in survival after brain RT
was observed over time, patients with HER2 positive brain metastases experienced significantly improved survival
subsequent to the availability of trastuzumab.
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The incidence of brain metastases appears to be in-
creasing as women with advanced breast cancer live
longer [1]. This is, in part, due to advances in the effi-
cacy of systemic therapy, resulting in improved control
of systemic disease, and improved imaging techniques
resulting in earlier diagnosis [2]. Historically, median
survival (MS) in untreated patients with metastatic dis-
ease to the brain has been reported to be one month* Correspondence: styldesley@bccancer.bc.ca
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reproduction in any medium, provided the or[3]. Following treatment with whole brain radiotherapy
(RT), a median survival of approximately 4–6 months
has been reported [3,4].
Human epidermal growth factor receptor 2 (HER2)
over-expression has been reported in 20%-25% of human
breast cancers and is associated with reduced overall
and disease-free survival [1,5]. Studies have demon-
strated improved overall survival (OS) and progression-
free survival with the use of trastuzumab in combination
with chemotherapy in the setting of metastatic breast
cancer in 1998 and in the adjuvant setting in 2004
[1,6,7]. Before the availability of trastuzumab, the major
factor limiting survival was the progression of systemic
disease. Since the introduction of trastuzumab, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dying from cerebral progression has increased [8].
Therefore, it is hypothesized that survival may be
improved after whole brain RT in patients with brain
metastases from breast cancer in the trastuzumab era
and this improvement may be related to improved sur-
vival in HER2 positive patients. Further, it is likely that
the increase survival maybe due to the impact of trastu-
zumab, and other diagnostic and therapeutic factors, ra-
ther than the biology of HER2 positive disease itself.
This is a report of the clinical characteristics, prognos-
tic variables, and outcomes of patients with HER2 posi-
tive and negative metastatic breast cancer who were
treated with brain RT before (preT-era) and after (T-era)
the availability of trastuzumab.Materials and methods
Study population
The BC Cancer Agency (BCCA) provides all radiation
therapy in the province of British Columbia (BC) for a
population of approximately 4.5 million. The BC Cancer
Registry contains demographic data on all incident can-
cers, and captures date and cause of death information
through a direct linkage to the BC Vital Statistics
Agency. In BC, stereotactic radiosurgery (SRS) for
patients with brain metastases was available after 1998.
Craniotomy has been practiced for decades in the prov-
ince in selected cases, but it became more widely
practiced during the 1990s after publication of the ran-
domized trial by Patchell et al. [9]. HER2 status has been
routinely tested in patients with breast cancer since
1999. Trastuzumab became available for patients with
metastatic breast cancer outside of a clinical trial setting
in August 1998.
A tissue microarray (TMA) of 4,444 patients with a
new diagnosis of invasive breast cancer in BC was cre-
ated from tumour specimens submitted to a central es-
trogen receptor (ER) laboratory, as previously described
[10]. Patients in the TMA cohort were all referred to
the BCCA and represented approximately 60% of all
breast cancer patients diagnosed in the province during
1986–1992. Single archival blocks were retained at the
Vancouver Hospital ER laboratory from each specimen
received for ER testing. For both the TMA subjects and
patients with clinical HER2 testing since 1999, HER2
status was determined using an immunohistochemistry
(IHC) technique. All IHC 2+ and indeterminate cases
were tested for gene amplification by fluorescence
in-situ hybridization (FISH). Tumors demonstrating no
or 1+ staining by IHC and/or no gene amplification by
FISH were scored as HER2 negative, whereas tumors
demonstrating 3+ staining by IHC and/or gene amplifi-
cation by FISH were scored as HER2 positive. When notumor could be identified on the HER2 slides, the
HER2 status was scored as unknown.
A total of 307 women with breast cancer diagnosed
between January 1986 and July 1992 (preT-era) and trea-
ted with whole brain RT were identified. Excluded from
this cohort were patients who had metastatic disease to
the skull without brain metastases (n = 2) and whose
paper charts were unavailable (n = 2). Of the remaining
cases, 128 were in the TMA series and had HER2 testing
performed. These 128 patients formed the preT-era co-
hort for the primary analysis.
Similarly, women were included in the T-era cohort if
they had a new diagnosis of breast cancer in BC between
January 2000 and December 2007 and they were treated
with whole brain RT. Patients who had leptomeningeal
disease at the time of whole brain RT (n = 7), metastatic
disease to the skull without brain metastases (n = 55)
and prophylactic cranial irradiation (n = 5) were excluded.
Therefore, a total of 441 patients formed the T-era cohort.
Patients diagnosed between 1992 and 2000 could not be
included in the analysis as no data on HER2 status was
available in that period, as HER2 status analysis was not
done as part of routine practice until after 2000.
Variables
The paper and electronic medical records of all patients
were reviewed. Data were collected regarding demo-
graphic and clinical characteristics including patient age,
M1 stage, grade, hormone receptor status and HER2 sta-
tus at the initial diagnosis of breast cancer. Brain metas-
tases treatment characteristics included craniotomy use,
brain RT dose, chemotherapy, hormone therapy and
trastuzumab use on or after the date of first brain metas-
tases. In addition, primary disease control status, exist-
ence of extracranial metastases and number of brain
lesions at the time of initial brain RT were abstracted.
Karnofsky performance status (KPS) (≥70 or <70) was
estimated retrospectively at the time point of the initial
diagnosis of brain metastases based on narrative notes
from attending clinicians in the BCCA chart.
A Recursive Partitioning Analysis (RPA) risk group
[11] was determined for each patient prior to initial
brain RT. The RPA risk group used four factors: age,
KPS, primary controlled/uncontrolled and the presence/
absence of extracranial metastases, from which, an RPA
class was assigned. Patients with KPS <70 were identified
as class 3; patients with KPS ≥70, controlled primary dis-
ease, age <65 years and absence of extracranial metasta-
ses were identified as class 1 and all other patients were
class 2 [11].
To address the potential bias of the TMA cohort from
the preT-era not being a subset of the 307 cases in the
population-based series, the 128 cases included in the
TMA and the 179 cases not included in the TMA cohort







n = 128 n = 441
Age (years) 0.017
<65 104 (81%) 345 (78%)
≥ 65 24 (19%) 96 (22%)
Median 53 (26–81) 55 (29–91)
M1 at diagnosis <0.001
Yes 5 (4%) 113 (26%)
No 115 (90%) 256 (58%)
Unknown 8 (6%) 72 (16%)
Tumor grade 0.084
1 0 (0%) 13 (3%)
2 24 (19%) 106 (24%)
3 95 (74%) 315 (71%)
Unknown 9 (7%) 7 (2%)
Hormone receptor status 0.83
ER+ 51 (40%) 180 (41%)
ER- 68 (53%) 249 (57%)
Unknown 9 (7%) 12 (3%)
HER2 status <0.001
Positive 33 (26%) 176 (40%)
Negative 87 (68%) 212 (48%)
Unknown 8 (6%) 53 (12%)
Time from diagnosis to BM (years) <0.001
Median 3.3 2.3
KPS at BM 0.76
<70 47 (37%) 170 (38%)
≥70 81 (63%) 271 (62%)
Number of BM 0.025
1 44 (34%) 117 (27%)
2-3 23 (18%) 73 (16%)
Multiple 61 (48%) 251 (57%)
Primary disease at BM 0.007
Controlled 104 (81%) 305 (70%)
Uncontrolled 24 (19%) 135 (31%)
Extracranial disease at BM 0.32
Brain only 22 (17%) 97 (22%)
Bone + brain 22 (17%) 76 (17%)
Visceral + brain +/−
bone
76 (59%) 245 (57%)
Other 8 (6%) 23 (5%)
RPA at BM 0.17
1 9 (7%) 55 (12%)
2 72 (56%) 219 (50%)
Table 1 Comparisons of clinicopathologic and treatment
characteristics by era (Continued)
3 47 (37%) 167 (39%)
Craniotomy 0.037
Yes 15 (12%) 87 (20%)
No 113 (88%) 354 (80%)
Trastuzumab at BM* -
Yes 0 (0%) 150 (34%)
No 128 (100%) 26 (5%)
Hormonal therapy at BM* <0.001
Yes 72 (56%) 100 (23%)
No 56 (44%) 341 (77%)
Chemotherapy at BM* 0.032
Yes 43 (34%) 194 (44%)
No 85 (66%) 242 (55%)
Unknown 0 (0%) 5 (1%)
* Refers to treatments given on or after the date of first brain metastases.
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor
receptor 2, KPS = Karnofsky performance status, BM = brain metastasis,
RPA = recursive partitioning analysis.
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after brain RT.
Statistical analysis
All analyses were conducted using the Statistical Package
for Social Sciences, version 14.0 (SPSS, Chicago, IL) and
the R statistical package, version 2.9.0 (http://cran.r-project.
org). Frequencies and descriptive statistics of demographic
and clinical variables were obtained. Categorical variables
were compared between eras using the Chi-Square test or
the Fisher’s Exact test, and continuous variables were com-
pared using the Student t-test. Unknown cases were
entered into the statistical tests for comparison. Survival
from the date of starting brain RT to death or last follow-
up was estimated using the Kaplan-Meier method, and
survival curves were compared using the log-rank test.
Multivariate predictors of survival were determined
using the Cox proportional-hazards model for both
eras. Variables included in the model were: HER2
overexpression, RPA class, ER status, number of brain
metastases, craniotomy, chemotherapy and hormone
therapy use, and SRS. Interaction terms were included
in the model between era and both hormonal therapy
and HER2 as the effects of these two variables were
different in the two eras. Age, primary status con-
trolled/uncontrolled, the presence/absence of extracra-
nial metastases, and KPS variables were not included
separately in the model, as the RPA class variable is
calculated using these variables. Hazard ratios and their
95% confidence intervals (95% CIs) were computed. A
p-value < 0.05 was considered to be statistically significant.
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Results
Comparison of outcomes in the preT-era according to
inclusion of the patient in the TMA series
In the preT-era, there were 307 women diagnosed with
metastatic breast cancer to the brain between January
1986 to July 1992, however, HER2 results are only avail-
able for cases included in the TMA for these years. Of the
307 cases, 42% (n = 128) were included in the TMA series
and 58% (n = 179) were not included in the TMA series.
The age distributions of the TMA and non-TMA subjects,
were similar (p = 0.56). Fourteen percent of the non-
TMA cases and 4% of the TMA cases had distant
metastases at diagnosis. One-year OS was similar in
the TMA and non-TMA cohorts (18% and 16%, p = 0.65).
All subsequent results reported for the pre-T era refer
only to the TMA cohort.
Patient, tumour and treatment characteristics
Table 1 summarizes patient, tumour and treatment char-
acteristics by era. Median age at diagnosis of brain me-
tastases was 55 years (range, 34–89 years) for the
T-era and 53 years (range, 26–77 years) for the preT-era,
(p = 0.017). The median time from diagnosis to brain RT
was longer in the preT-era (3.3 years versus 2.3 years, p
< 0.001). The rates of HER2 positive disease were 40%
(n = 176/441) in the T-era and 26% (n = 33/128) in the
preT-era cohorts (p < 0.001). In the T-era, among women
with HER2 positive disease, 85% (150/176) received tras-
tuzumab after a diagnosis of brain metastases as com-
pared to none in the preT-era. There were no significant
differences in other baseline variables (Table 1).
All women received whole brain RT for their brain
metastases. Overall, the three most common prescrip-
tions were 20 Gy in 5 fractions (preT-era: 85% (109/128);
T-era: 64% (282/441); p < 0.05), 30 Gy in 10 fractions
(preT-era: 4% (5/128); T-era: 24% (105/441); p < 0.05) and
20 Gy in 4 fractions (preT-era: 4% (5/128); T-era: 4%
(17/441); p < 0.50). Three percent of women (15/441) had
SRS in the T-era as a component of their initial brain me-
tastases treatment.
Survival
One-year OS rates were 12% in the preT-era and 26% in
the T-era (p < 0.001). Among patients with HER2 negative
disease, 1-year OS rates were 20% for both preT- and
T-eras (MS: preT-era: 3.2 months, T-era: 3.7 months,
p = 0.97) (Figure 1). Among patients with HER2 positive
disease in the preT-era and T-era, 1-year OS rates were 5%
and 40% (MS: preT-era: 3.4 months, T-era: 6.8 months,
p < 0.001) (Figure 2). Women with RPA class 3 had a me-
dian survival in both eras of 1.8 months (preT-era) versus2.7 months (T-era) (p = 0.37), whereas those with more
favourable prognostic features had a longer median survival
in the T-era (class 1: preT-era: 6.2 months, T-era:
14.5 months, p = 0.006 and class 2: preT-era: 3.9 months,
T-era: 6.4 months, p = 0.001) (Figure 3).
On univariate analysis of patients in the preT-era, RPA
class at diagnosis of brain metastases (p = 0.025), use of
craniotomy (p < 0.005), the presence of a solitary brain
lesion (p < 0.034), and ER positive status (p = 0.013),
were associated with improved survival. In the T-era
cohort, RPA class at diagnosis of brain metastases
(p < 0.001), SRS boost at initial brain metastases
(p < 0.001), use of craniotomy (p < 0.001), the presence
of a solitary brain lesion (p < 0.001), HER2 overexpres-
sion (p < 0.001), chemotherapy use (p < 0.001), hormo-
nal therapy use (p < 0.001) and trastuzumab therapy
use (p < 0.001) at brain metastases were favourable
prognostic factors for survival.
Table 2 summarizes the results from a multivariable
model for OS combining data from both eras. In the
T-era, women with HER2 positive disease had a statisti-
cally significant lower risk of death compared to those
with HER2 negative disease (HR, 0.49, 95% CI: 0.39,
0.62; p < 0.001). However, in the preT-era, HER2 overex-
pression was not significantly associated with survival
(HR, 1.02, 95% CI: 0.66, 1.58, p = 0.92). Hormonal ther-
apy was significantly associated with improved survival
(HR, 0.62, 95% CI: 0.46, 0.84, p = 0.002) in the T-era
compared to the preT-era (HR, 1.09, 95% CI: 0.73, 1.61,
p = 0.68). Women with RPA class 3 had a higher risk of
death compared to those with RPA class 1 (HR, 3.65;
95% CI, 2.52, 5.27; p < 0.001); RPA class 2 also had an
elevated risk of death compared to class 1 (HR, 1.60;
95% CI, 1.12, 2.27; p = 0.009). Other significant prognos-
tic factors included craniotomy use (p < 0.001), ER posi-
tive status (p = 0.001), chemotherapy use (p < 0.001),
number of brain lesions (4+ lesions vs. 1, p = 0.017; 2–3
lesions vs. 1, p = 0.805) and SRS boost (p = 0.003).
Discussion
This population-based study evaluated outcomes and
prognostic factors in patients with metastatic breast
cancer treated with whole brain RT in a contemporary
era compared to an era prior to the availability of
trastuzumab.
Several retrospective studies have investigated on sur-
vival after the diagnosis of brain metastases in HER2
positive patients, and only one has included HER2 posi-
tive cases from a pre-trastuzumab era [12-16]. Eichler
et al. identified 83 patients with breast cancer and new
brain metastases diagnosed between 2001 and 2005, and
found that the median survival from the time of brain
metastases was 8.3 months. On univariate analysis,
HER2 positive patients were found to have prolonged
Figure 1 Overall survival by era: HER2 negative patients.
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negative patients (17.1 months vs 5.2 months) [15].
Bendell et al. identified 122 women with breast cancer
treated with trastuzumab and reported that 42 patients
(34%) developed cerebral disease with a median survival
of 13 months from the time of brain metastases diagno-
sis [13]. Stemmler et al. reported on 42 patients with
HER2 positive disease with a MS of 13 months after
treatment with trastuzumab at the time of brain metas-
tases [14]. In the analysis by Bartsch et al., 80 patients
with brain metastasis from HER2-positive breast cancer
were identified. In addition, a control group of 37
patients treated before 2003, when continuation of tras-
tuzumab after diagnosis of brain metastasis was not yet
advised, were also included [16]. They reported that the
MS in patients receiving trastuzumab after diagnosis of
BM was 13 months, compared to 3 months in patients
treated with radiotherapy alone [16].
In the current series of 441 patients treated with whole
brain RT in the T-era, a one-year OS of 26% compared
to 12% for 128 patients treated in the preT-era was
reported. Among HER2 negative patients, the 1-year OSFigure 2 Overall survival by era: HER2 positive patients.(20%) and median survival was similar in the two eras
(preT-era: 3.7 months; T-era: 3.2 months). This is com-
parable to the median OS of approximately 4 months
reported in historical analyses of breast cancer patients
with brain metastases [12,16-18]. However, for the HER2
positive patients, the absolute 1-year OS was significantly
increased by 35% in the T-era from 5% to 40% and the me-
dian survival was increased by 3 months in the T-era from
3.4 months to 6.8 months.
The reasons behind the survival advantage for patients
with HER2 positive disease may be explained by better
systemic control outside the brain with trastuzumab or
other systemic agents in the 2000s compared to the early
1990s [2]. It is also possible that trastuzumab itself con-
tributes to local brain disease control by penetrating the
brain at areas where the blood–brain barrier is disrupted
following RT or that trastuzumab and RT have a syner-
gistic effect on brain metastases.
On multivariable analysis, there were significant inter-
actions between the era and both the use of hormonal
therapy and HER2 expression. Survival was improved in
the T-era for patients with HER2 overexpression and
who received hormonal therapy. As the treatment era
variable appears to interact with both HER2 overexpres-
sion and hormonal therapy, the interpretation of era ef-
fect on survival outcomes requires one to consider both
HER2 status and hormonal therapy use. The era variable
could not be reported as was done for terms that did
not interact with other variables.
Moreover, the fact that 14% of the non-TMA cases
were metastatic at initial diagnosis versus only 4% of the
TMA cases implies that there may have been a referral
bias to the frozen tissue archive used to make the TMA.
However, if anything, the paucity of metastatic cases at
presentation in the TMA cohort would tend to make the
study outcomes better in the pre-T era, which was not
observed. The absolute difference in 1-year OS following
diagnosis of brain metastases was only 2% when com-
paring the TMA and non-TMA cases diagnosed in the
preT-era. Therefore, possible TMA referral bias is un-
likely to explain the difference in overall survival in the
HER2 positive cases between the two eras.
There are several potential limitations in the current
study. First, some of the data such as performance status
were assigned retrospectively based on the description in
the chart, decreasing the discrimination of the perform-
ance status categories. Data on toxicity could not be
abstracted due to the limitations of a retrospective de-
sign. In addition, there is the possibility of lead time bias,
in which greater use and access to cross-sectional, and
particularly MRI imaging in the 2000s compared to
1990s may have led to an earlier diagnosis of brain me-
tastases and hence contributed to the longer observed
survival between eras.
Figure 3 Overall survival by era and RPA class: (A) RPA 1; (B)
RPA 2; (C) RPA 3.
Table 2 Multivariate analysis of overall survival including
patients from both Pre-Trastuzumab and Trastuzumab
eras
Characteristics HR (95% CI) p-value
RPA
1 1 [Reference]
2 1.59 (1.12, 2.27) 0.009
3 3.64 (2.52, 5.27) <0.001
ER status
Negative 1 [Reference]
Positive 0.67 (0.54, 0.84) 0.001
Number of brain lesions
1 1 [Reference]
2-3 1.04 (0.77, 1.41) 0.80
Multiple 1.36 (1.06, 1.75) 0.017
Craniotomy
No 1 [Reference]
Yes 0.43 (0.31, 0.58) <0.001
Chemotherapy
No 1 [Reference]
Yes 0.59 (0.49, 0.73) <0.001
SRS boost
No 1 [Reference]
Yes 0.40 (0.22, 0.73) 0.003
HER2 (positive vs. negative)
preT-era 1.02 (0.66, 1.58) 0.92
T-era 0.49 (0.39, 0.62) <0.001
Hormonal therapy (yes vs. no)
preT-era 1.09 (0.73, 1.61) 0.68
T-era 0.62 (0.46, 0.84) 0.002
Abbreviations: RPA = recursive partitioning analysis, ER = estrogen receptor,
SRS = stereotactic radiosurgery, HER2 = human epidermal growth factor
receptor 2.
Karam et al. Radiation Oncology 2013, 8:12 Page 6 of 7
http://www.ro-journal.com/content/8/1/12The RPA prognostic index developed by Gaspar et al.
was used in this study but did not account for the primary
site as a prognostic parameter and did not include the
number of brain lesions [11]. The significance of diagnosis-
specific prognostic factors has been demonstrated in the
Graded Prognostic Assessment (GPA) developed by Sper-
duto et al. [19-21]. Among patients with breast cancer, the
only significant prognostic factor reported was the KPS
[19-21]. The current study did not use the GPA index, since
the use of the full range of KPS classifications was often notdocumented explicitly in the chart, as the case would be for
most retrospective studies.Conclusion
This contemporary study demonstrates that subsequent to
the availability of trastuzumab, the 1-year OS after brain
RT was improved by 35% for HER2 positive patients com-
pared to counterparts diagnosed and treated prior to the
availability of trastuzumab. As survival was increased in the
trastuzumab era only among patients with HER2 positive
disease, this suggests that it is the use of trastuzumab or
other factors, such as a possible beneficial interaction be-
tween RT and trastuzumab that have improved survival, ra-
ther than a characteristic of the biology, or natural history,
of HER2 positive disease itself.
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